News

Copycats attack Abbott's Humira
Enlarge image

BusinessSwitzerlandGermanyMalta

Copycats attack Abbott's Humira

31.10.2012 - With AET Biotech Ltd. and BioXpress SA, two new players join the queue of Humira copycats.

The two partners pool their expertise in the manufacturing of biologicals and in development and marketing. The TNF-alpha blocker is a promising target with projected global sales of more US$9bn this year. Malta-based AET BioTech Ltd. is the biosimilars operation of German generic drugs firm Alfred E. Tiefenbacher GmbH & Co. KG in Hamburg. BioXpress S.A. is a Swiss biotech focused on the development of monoclonal antibody biosimilars.

The firms aim to jointly develop the biosimilar to registration, based on BioXpress expression technology. AET will shoulder commercialisation of the resulting antibody and will, in addition, provide further investment in terms of committed long-term financing.
The Humira patent runs out in 2016. However, Abbott is trying to prevent biosimilar competition by legal action. Furthermore, larger players like Boehringer Ingelheim are already developing Humira follow-on biologics. Humira has an interesting history. Originally the drug was developed by German BASF AG who sold its pharma business to Abbott.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/copycats-attack-abbotts-blockbuster.html

LicencingDenmark

05.03.2015 Bavarian Nordic is outlicensing its Phase 3 prostate cancer immunotherapy Prostvac to pharma heavyweight Bristol Myers Squibb for a tidy €881m.

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.47 CHF27.03%
  • BIOFRONTERA2.07 EUR4.02%
  • FORMYCON17.40 EUR3.02%

FLOP

  • STRATEC BIOMEDICAL43.50 EUR-3.59%
  • MEDIGENE4.55 EUR-1.94%
  • EVONIK30.88 EUR-1.66%

TOP

  • WILEX3.15 EUR47.9%
  • CYTOS0.47 CHF38.2%
  • EVOLVA1.69 CHF18.2%

FLOP

  • MOLOGEN5.27 EUR-13.7%
  • SANTHERA97.20 CHF-11.4%
  • 4SC0.77 EUR-9.4%

TOP

  • SANTHERA97.20 CHF2424.7%
  • WILEX3.15 EUR400.0%
  • FORMYCON17.40 EUR122.2%

FLOP

  • CYTOS0.47 CHF-83.4%
  • MOLOGEN5.27 EUR-57.2%
  • PAION2.09 EUR-55.5%

No liability assumed, Date: 04.03.2015